The Week in Review: CROs Consolidating

WuXi PharmaTech (药明康德), continuing the string of China CRO consolidations, agreed to be acquired by Charles River Laboratories for $1.6 billion; Aoxing Pharma and Johnson Matthey will establish a JV to develop APIs; Bayer AG’s 2009 China revenues totaled $709 million; the China operations of AlphaRx will complete a reverse merger with Pacific Orient Capital; PPD has opened a vaccine clinical research center in Taizhou’s China Medical City; a China Biologic Products subsidiary was named one of twelve model companies; China Pediatric Pharma reported a rise in 2009 revenues; and China Medical Technologies (中国医疗技术公司) received approval for a fully-automated ECLIA analyzer. More details… Stock Symbols: (NYSE: WX) (NYSE: CRL) (AMEX: AXN) (XETRA: BAY) (OTCBB: ALRX) (NSDQ: PPDI) (NSDQ: CBPO) (OTCBB: CPDU) (NSDQ: CMED)